A Phase 2 interventional study of TEV-56286 and Placebo in Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Active, not recruiting at 61 sites in 8 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.
Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 7th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 in phase 2, reaches primary completion later than 23 of the 31 other live ones, and was the 79th registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
MODAG GmbH · Sites in United States
Ages 18–60 · Healthy volunteers
MODAG GmbH · Sites in United States
Ages 50–80 · Healthy volunteers
Teva Branded Pharmaceutical Products R&D LLC · Sites in United States, France, Germany and 4 more countries
Ages 30+
Tiziana Life Sciences LTD · Sites in United States
Ages 30–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 20 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 349 is above the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 35 across the 57 interventional studies, 184 across the 31 observational. Of the 53 that completed or were terminated, 19 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 90 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D LLC, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D LLC is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 3 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
19 of the studies in Multiple System Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT05167721Mayo ClinicRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | 2026-12 |
| NCT02726711Vanderbilt UniversityReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | 2026-12 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
Add all 19 to your calendar (.ics) → With an account.
Among the 90 studies in Multiple System Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286.
Another secondary objective is to evaluate the safety and tolerability of TEV-56286.
The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
We plan to open locations in the following countries: US, Israel, Italy, Spain, Germany, France, Japan, and Serbia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males who are potentially fertile/reproductively competent (not surgically [eg, vasectomy] or congenitally sterile) and their female partners who are of CBP must use, together with their female partners, highly effective birth control methods
Exclusion Criteria:
participant is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally administered capsules once daily
Drug: TEV-56286
Orally administered capsules once daily
Drug: Placebo
TEV-56286 capsules administered orally
Also known as: emrusolmin, anle138b
Matching placebo administered orally
For non-EU: Change From Baseline in the Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Score (excluding item 11)
The UMSARS is a multidimensional, validated scale for semi-quantitative clinical assessments of MSA participants. Modified UMSARS part I includes all items with the exclusion of item 11. Item scoring is scaled 0-3 using a range of 0 (no impairment) to 3 (severe impairment).
Time frame: Baseline to Week 48
For EU: Change From Baseline in the Total UMSARS Score Part I and Part II Combined
The UMSARS is comprised of 4 parts: part I, historical review of disease-related impairments, 12 items and part II, motor examination, 14 items. As UMSARS is a unified scale, each item in parts I and II achieves a single score using a range of 0 (no impairment) to 4 (severe impairment).
Time frame: Baseline to Week 48
For non-EU: Change From Baseline in the Total UMSARS Score (Part I and Part II combined)
Time frame: Baseline to Week 48
For EU: Change From Baseline in the Modified UMSARS part I score (excluding item 11, item scoring rescaled 0-3)
Time frame: Baseline to Week 48
Change From Baseline in the UMSARS Part 1 Score
Time frame: Baseline to Week 48
Change From Baseline in Lateral Ventricle Volume Measured by MRI
Time frame: Baseline to Week 48
Change From Baseline in the Clinical Global Impression - Severity scale (CGI-S)
The CGI-S scale permits a global evaluation of the participant's current severity of illness on a Likert type scale ranging from 1 to 7, where 1=normal/not at all ill, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill participants
Time frame: Baseline to Week 48
Change From Baseline in the Neurofilament Light Chain (NfL) Concentrations in Cerebrospinal Fluid (CSF)
Time frame: Baseline to Week 48
Change From Baseline in the Patient Global Impression-Severity Scale (PGI-S)
The PGI-S scale permits an evaluation of the participant's MSA severity, according to the participant. The PGI-S scale rates the participant's MSA severity on a 5-point Likert type scale ranging from 0 (not severe) to 4 (very severe)
Time frame: Baseline to Week 48
Change From Baseline in the Pons volume measured by MRI
Time frame: Baseline to Week 48
Change From Baseline in the Cerebellar volume measured by MRI
Time frame: Baseline to Week 48
Change From Baseline in the UMSARS part II score
Time frame: Baseline to Week 48
Change From Baseline in the UMSARS part IV score
Time frame: Baseline to Week 48
Change From Baseline in the Two-minute walk test as part of gait assessment
Time frame: Baseline to Week 48
Change From Baseline in the Multiple System Atrophy - Quality of Life (MSA-QoL) Score
The 40-item MSA-QoL questionnaire is self-administered and each item is rated on a Likert type scale (0: No problem) to (4: Extreme problem). It is comprised of 3 subscales relevant to MSA: motor (14 items), non-motor (12 items), and emotional/social (14 items). The MSA-QoL total score is the sum of all the items and lower scores indicate better QoL.
Time frame: Baseline to Week 48
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAEs)
Time frame: Up to Week 48
Number of Participants Who Withdraw From the Study Due to an Adverse Event
Time frame: Up to Week 48
Number of Participants Who Withdraw From Treatment Due to an Adverse Event
Time frame: Up to Week 48
Number of Participants With At Least One Potentially Clinically Significant Abnormal Vital Sign Value
Time frame: Up to Week 48
Number of Participants With At Least One Potentially Clinically Significant Laboratory Test Value
Time frame: Up to Week 48
Number of Participants with at Least One Potentially Clinically Significant Change in 12-lead Electrocardiogram (ECG) Findings
Time frame: Up to Week 48
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teva Branded Pharmaceutical Products R&D LLC →